6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O

PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
,	,	,	,	,	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
CNS	NNP	cns	cns	cn	N	B-AdverseReaction
PTLD	NNP	ptld	ptld	ptld	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
JC	NNP	jc	jc	jc	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
and	CC	and	and	and	N	O
polyoma	VB	polyoma	polyoma	polyoma	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
nephropathy	JJ	nephropathy	nephropathy	nephropathi	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
,	,	,	,	,	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
on	IN	on	on	on	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
treatment	NN	treatment	treatment	treatment	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
anemia	JJ	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
graft	NN	graft	graft	graft	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperkalemia	NN	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Bristol	NNP	bristol	bristol	bristol	N	O
-	:	-	-	-	N	O
Myers	NNS	myers	myers	myer	N	O
Squibb	VBP	squibb	squibb	squibb	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
721	CD	721	721	721	N	O
-	:	-	-	-	N	O
5072	CD	5072	5072	5072	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
primarily	RB	primarily	primarily	primarili	N	O
derive	JJ	derive	derive	deriv	N	O
from	IN	from	from	from	N	O
two	CD	two	two	two	N	O
randomized	NNS	randomized	randomized	random	N	O
,	,	,	,	,	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
three	CD	three	three	three	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
in	IN	in	in	in	N	O
de	NNP	de	de	de	N	O
novo	FW	novo	novo	novo	N	O
kidney	NN	kidney	kidney	kidney	N	O
transplant	NN	transplant	transplant	transplant	Y	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
401	CD	401	401	401	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
regimen	NNS	regimen	regimen	regimen	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
405	CD	405	405	405	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
two	CD	two	two	two	N	O
trials	NNS	trials	trial	trial	N	O
also	RB	also	also	also	N	O
included	VBD	included	included	includ	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
403	CD	403	403	403	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NN	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
higher	JJR	higher	higher	higher	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
dosing	NN	dosing	dosing	dose	N	O
than	IN	than	than	than	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
also	RB	also	also	also	N	O
received	VBD	received	received	receiv	N	O
basiliximab	JJ	basiliximab	basiliximab	basiliximab	N	O
induction	NN	induction	induction	induct	N	O
,	,	,	,	,	N	O
mycophenolate	NN	mycophenolate	mycophenolate	mycophenol	N	O
mofetil	NN	mofetil	mofetil	mofetil	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
and	CC	and	and	and	N	O
followed	VBN	followed	followed	follow	N	O
for	IN	for	for	for	N	O
3	CD	3	3	3	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

CNS	NNP	cns	cns	cn	N	B-AdverseReaction
PTLD	NNP	ptld	ptld	ptld	N	I-AdverseReaction
,	,	,	,	,	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
CNS	NNP	cns	cns	cn	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NN	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
higher	JJR	higher	higher	higher	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
dosing	NN	dosing	dosing	dose	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
;	:	;	;	;	N	O
therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
dosing	NN	dosing	dosing	dose	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
average	JJ	average	average	averag	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
cyclosporine	VB	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
regimens	NNS	regimens	regimen	regimen	N	O
was	VBD	was	wa	wa	N	O
49	CD	49	49	49	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
79	CD	79	79	79	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
70%	CD	70%	70%	70%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
;	:	;	;	;	N	O
67%	CD	67%	67%	67%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
,	,	,	,	,	N	O
11%	CD	11%	11%	11%	N	O
were	VBD	were	were	were	N	O
black	JJ	black	black	black	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
22%	CD	22%	22%	22%	N	O
other	JJ	other	other	other	N	O
races	NNS	races	race	race	N	O
.	.	.	.	.	N	O

About	IN	about	about	about	N	O
25%	CD	25%	25%	25%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
United	NNP	united	united	unit	N	O
States	NNPS	states	state	state	N	O
and	CC	and	and	and	N	O
75%	CD	75%	75%	75%	N	O
from	IN	from	from	from	N	O
other	JJ	other	other	other	N	O
countries	NNS	countries	country	countri	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
cannot	JJ	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
20%	CD	20%	20%	20%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
were	VBD	were	were	were	N	O
anemia	RB	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
graft	NN	graft	graft	graft	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperkalemia	NN	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
13%	CD	13%	13%	13%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
and	CC	and	and	and	N	O
19%	CD	19%	19%	19%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
arm	NN	arm	arm	arm	N	O
through	IN	through	through	through	N	O
three	CD	three	three	three	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
cytomegalovirus	JJ	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
complications	NNS	complications	complication	complic	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
transplanted	JJ	transplanted	transplanted	transplant	N	I-AdverseReaction
kidney	NN	kidney	kidney	kidney	N	I-AdverseReaction
(	(	(	(	(	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Information	NN	information	information	inform	N	O
on	IN	on	on	on	N	O
selected	VBN	selected	selected	select	N	O
significant	JJ	significant	significant	signific	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBD	observed	observed	observ	N	O
during	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
is	VBZ	is	is	is	N	O
summarized	VBN	summarized	summarized	summar	N	O
below	IN	below	below	below	N	O
.	.	.	.	.	N	O

Post	NNP	post	post	post	N	O
-	:	-	-	-	N	O
Transplant	NN	transplant	transplant	transplant	Y	O
Lymphoproliferative	JJ	lymphoproliferative	lymphoproliferative	lymphoprolif	N	O
Disorder	NN	disorder	disorder	disord	N	O

Reported	VBN	reported	reported	report	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
post	NN	post	post	post	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
transplant	NN	transplant	transplant	transplant	Y	I-AdverseReaction
lymphoproliferative	JJ	lymphoproliferative	lymphoproliferative	lymphoprolif	N	I-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
)	)	)	)	)	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
36	CD	36	36	36	N	O
months	NNS	months	month	month	N	O
post	VBN	post	post	post	N	O
transplant	NN	transplant	transplant	transplant	Y	O
were	VBD	were	were	were	N	O
obtained	VBN	obtained	obtained	obtain	N	O
for	IN	for	for	for	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
by	IN	by	by	by	N	O
pooling	VBG	pooling	pooling	pool	N	O
both	DT	both	both	both	N	O
dosage	NN	dosage	dosage	dosag	N	O
regimens	NNS	regimens	regimen	regimen	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
804	CD	804	804	804	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
third	JJ	third	third	third	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
kidney	NN	kidney	kidney	kidney	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
145	CD	145	145	145	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
which	WDT	which	which	which	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
two	CD	two	two	two	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
dosage	NN	dosage	dosage	dosag	N	O
regimens	VBZ	regimens	regimen	regimen	N	O
similar	JJ	similar	similar	similar	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
slightly	RB	slightly	slightly	slightli	N	O
different	JJ	different	different	differ	N	O
,	,	,	,	,	N	O
from	IN	from	from	from	N	O
those	DT	those	those	those	N	O
of	IN	of	of	of	N	O
Studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
total	JJ	total	total	total	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
patients	NNS	patients	patient	patient	N	O
from	IN	from	from	from	N	O
these	DT	these	these	these	N	O
three	CD	three	three	three	N	O
studies	NNS	studies	study	studi	N	O
(	(	(	(	(	N	O
949	CD	949	949	949	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
groups	NNS	groups	group	group	N	O
from	IN	from	from	from	N	O
all	DT	all	all	all	N	O
three	CD	three	three	three	N	O
studies	NNS	studies	study	studi	N	O
(	(	(	(	(	N	O
476	CD	476	476	476	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
401	CD	401	401	401	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
71	CD	71	71	71	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
very	RB	very	very	veri	N	O
similar	JJ	similar	similar	similar	N	O
(	(	(	(	(	N	O
but	CC	but	but	but	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
identical	JJ	identical	identical	ident	N	O
)	)	)	)	)	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
5	CD	5	5	5	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
:	:	:	:	:	N	O
3	CD	3	3	3	N	O
in	IN	in	in	in	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
in	IN	in	in	in	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seronegative	JJ	seronegative	seronegative	seroneg	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
5	CD	5	5	5	N	O
cases	NNS	cases	case	case	N	O
presented	VBN	presented	presented	present	N	O
with	IN	with	with	with	N	O
CNS	NNP	cns	cns	cn	N	O
involvement	NN	involvement	involvement	involv	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
477	CD	477	477	477	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
higher	JJR	higher	higher	higher	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
dosing	NN	dosing	dosing	dose	N	O
than	IN	than	than	than	N	O
recommended	VBN	recommended	recommended	recommend	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
8	CD	8	8	8	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
:	:	:	:	:	N	O
2	CD	2	2	2	N	O
in	IN	in	in	in	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
6	CD	6	6	6	N	O
in	IN	in	in	in	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seronegative	NN	seronegative	seronegative	seroneg	N	O
or	CC	or	or	or	N	O
serostatus	VB	serostatus	serostatus	serostatu	N	O
unknown	JJ	unknown	unknown	unknown	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Six	CD	six	six	six	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
8	CD	8	8	8	N	O
cases	NNS	cases	case	case	N	O
presented	VBN	presented	presented	present	N	O
with	IN	with	with	with	N	O
CNS	NNP	cns	cns	cn	N	O
involvement	NN	involvement	involvement	involv	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
dosing	NN	dosing	dosing	dose	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

One	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
476	CD	476	476	476	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
developed	VBN	developed	developed	develop	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
,	,	,	,	,	N	O
without	IN	without	without	without	N	O
CNS	NNP	cns	cns	cn	N	O
involvement	NN	involvement	involvement	involv	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
reported	VBD	reported	reported	report	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
36	CD	36	36	36	N	O
months	NNS	months	month	month	N	O
post	VBN	post	post	post	N	O
transplant	NN	transplant	transplant	transplant	Y	O
in	IN	in	in	in	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
cyclosporine	VB	cyclosporine	cyclosporine	cyclosporin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
presented	VBD	presented	presented	present	N	O
within	IN	within	within	within	N	O
18	CD	18	18	18	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
in	IN	in	in	in	N	O
949	CD	949	949	949	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimens	NNS	regimens	regimen	regimen	N	O
was	VBD	was	wa	wa	N	O
9	CD	9	9	9	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seronegative	JJ	seronegative	seronegative	seroneg	N	O
or	CC	or	or	or	N	O
EBV	NNP	ebv	ebv	ebv	N	O
serostatus	VBP	serostatus	serostatus	serostatu	N	O
unknown	JJ	unknown	unknown	unknown	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
139	CD	139	139	139	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
810	CD	810	810	810	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
only	RB	only	only	onli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
and	CC	and	and	and	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Summary	NN	summary	summary	summari	N	O
of	IN	of	of	of	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
Reported	NNP	reported	reported	report	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
Through	IN	through	through	through	N	O
Three	CD	three	three	three	N	O
Years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
Treatment	NN	treatment	treatment	treatment	N	O

NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
Recommended	VBN	recommended	recommended	recommend	N	O
Regimen	NNP	regimen	regimen	regimen	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
477	CD	477	477	477	N	O
)	)	)	)	)	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
Recommended	NNP	recommended	recommended	recommend	N	O
Regimen	NNP	regimen	regimen	regimen	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
472	CD	472	472	472	N	O
)	)	)	)	)	N	O
Cyclosporine	NNP	cyclosporine	cyclosporine	cyclosporin	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
476	CD	476	476	476	N	O
)	)	)	)	)	N	O

Trial	JJ	trial	trial	trial	N	O
EBV	NNP	ebv	ebv	ebv	N	O
Positive	NNP	positive	positive	posit	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
406	CD	406	406	406	N	O
)	)	)	)	)	N	O
EBV	NNP	ebv	ebv	ebv	N	O
Negative	NNP	negative	negative	neg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
43	CD	43	43	43	N	O
)	)	)	)	)	N	O
EBV	NNP	ebv	ebv	ebv	N	O
Unknown	NNP	unknown	unknown	unknown	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
28	CD	28	28	28	N	O
)	)	)	)	)	N	O
EBV	NNP	ebv	ebv	ebv	N	O
Positive	NNP	positive	positive	posit	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
404	CD	404	404	404	N	O
)	)	)	)	)	N	O
EBV	NNP	ebv	ebv	ebv	N	O
Negative	NNP	negative	negative	neg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
48	CD	48	48	48	N	O
)	)	)	)	)	N	O
EBV	NNP	ebv	ebv	ebv	N	O
Unknown	NNP	unknown	unknown	unknown	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O
EBV	NNP	ebv	ebv	ebv	N	O
Positive	NNP	positive	positive	posit	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
399	CD	399	399	399	N	O
)	)	)	)	)	N	O
EBV	NNP	ebv	ebv	ebv	N	O
Negative	NNP	negative	negative	neg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
EBV	NNP	ebv	ebv	ebv	N	O
Unknown	NNP	unknown	unknown	unknown	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O

Regimen	NNS	regimen	regimen	regimen	N	O

with	IN	with	with	with	N	O
higher	JJR	higher	higher	higher	N	O
cumulative	NN	cumulative	cumulative	cumul	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
dosing	NN	dosing	dosing	dose	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
is	VBZ	is	is	is	N	O
identical	JJ	identical	identical	ident	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
is	VBZ	is	is	is	N	O
slightly	RB	slightly	slightly	slightli	N	O
different	JJ	different	different	differ	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Study	NN	study	study	studi	N	O

1	CD	1	1	1	N	O

CNS	NNP	cns	cns	cn	N	B-AdverseReaction
PTLD	NNP	ptld	ptld	ptld	N	I-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
CNSPTLD	NNP	cnsptld	cnsptld	cnsptld	N	I-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O

CNS	NNP	cns	cns	cn	N	B-AdverseReaction
PTLD	NNP	ptld	ptld	ptld	N	I-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
CNSPTLD	NN	cnsptld	cnsptld	cnsptld	N	I-AdverseReaction
1	CD	1	1	1	N	O

Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O

CNS	NNP	cns	cns	cn	N	B-AdverseReaction
PTLD	NNP	ptld	ptld	ptld	N	I-AdverseReaction
2	CD	2	2	2	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
CNSPTLD	NN	cnsptld	cnsptld	cnsptld	N	I-AdverseReaction
1	CD	1	1	1	N	O

Total	NNP	total	total	total	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.5	CD	0.5	0.5	0.5	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
11.6	CD	11.6	11.6	11.6	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
3.6	CD	3.6	3.6	3.6	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.7	CD	0.7	0.7	0.7	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
4.1	CD	4.1	4.1	4.1	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1.8	CD	1.8	1.8	1.8	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

EBV	NNP	ebv	ebv	ebv	N	O
Seropositive	NNP	seropositive	seropositive	seroposit	N	O
Subpopulation	NNP	subpopulation	subpopulation	subpopul	N	O

Among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
806	CD	806	806	806	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
CMV	NNP	cmv	cmv	cmv	N	O
serostatus	NN	serostatus	serostatus	serostatu	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
either	DT	either	either	either	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
two	CD	two	two	two	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
;	:	;	;	;	N	O
4	CD	4	4	4	N	O
210	CD	210	210	210	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
CMV	NNP	cmv	cmv	cmv	N	O
seronegative	JJ	seronegative	seronegative	seroneg	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
596	CD	596	596	596	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
CMV	NNP	cmv	cmv	cmv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
404	CD	404	404	404	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
recipients	NNS	recipients	recipient	recipi	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
dosage	NN	dosage	dosage	dosag	N	O
regimen	NNS	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
,	,	,	,	,	N	O
three	CD	three	three	three	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
were	VBD	were	were	were	N	O
detected	VBN	detected	detected	detect	N	O
among	IN	among	among	among	N	O
99	CD	99	99	99	N	O
CMV	NNP	cmv	cmv	cmv	N	O
seronegative	JJ	seronegative	seronegative	seroneg	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
no	DT	no	no	no	N	O
case	NN	case	case	case	N	O
detected	VBD	detected	detected	detect	N	O
among	IN	among	among	among	N	O
303	CD	303	303	303	N	O
CMV	NNP	cmv	cmv	cmv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
CMV	NNP	cmv	cmv	cmv	N	O
serology	NN	serology	serology	serolog	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	O
factor	NN	factor	factor	factor	N	O
for	IN	for	for	for	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
remains	VBZ	remains	remains	remain	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
determined	VBN	determined	determined	determin	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
findings	NNS	findings	finding	find	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
when	WRB	when	when	when	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	O

Malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
non	SYM	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
melanoma	NN	melanoma	melanoma	melanoma	Y	I-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
and	CC	and	and	and	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
in	IN	in	in	in	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
401	CD	401	401	401	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
and	CC	and	and	and	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
405	CD	405	405	405	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
melanoma	NN	melanoma	melanoma	melanoma	Y	I-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
401	CD	401	401	401	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
405	CD	405	405	405	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
cyclosporine	JJ	cyclosporine	cyclosporine	cyclosporin	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Progressive	JJ	progressive	progressive	progress	N	O
Multifocal	NNP	multifocal	multifocal	multifoc	N	O
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O

Two	CD	two	two	two	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
progressive	JJ	progressive	progressive	progress	N	B-AdverseReaction
multifocal	JJ	multifocal	multifocal	multifoc	N	I-AdverseReaction
leukoencephalopathy	NN	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
among	IN	among	among	among	N	O
1096	CD	1096	1096	1096	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
containing	VBG	containing	containing	contain	N	O
regimen	NNS	regimen	regimen	regimen	N	O
:	:	:	:	:	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
kidney	NN	kidney	kidney	kidney	N	O
transplant	NN	transplant	transplant	transplant	Y	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
described	NNS	described	described	describ	N	O
above	IN	above	above	abov	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
liver	NN	liver	liver	liver	N	O
transplant	NN	transplant	transplant	transplant	Y	O
(	(	(	(	(	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
250	CD	250	250	250	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
control	JJ	control	control	control	N	O
regimen	NNS	regimen	regimen	regimen	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
kidney	NN	kidney	kidney	kidney	N	O
transplant	NN	transplant	transplant	transplant	Y	O
recipient	NN	recipient	recipient	recipi	N	O
was	VBD	was	wa	wa	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
higher	JJR	higher	higher	higher	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
dosing	NN	dosing	dosing	dose	N	O
than	IN	than	than	than	N	O
recommended	VBN	recommended	recommended	recommend	N	O
,	,	,	,	,	N	O
mycophenolate	VB	mycophenolate	mycophenolate	mycophenol	N	O
mofetil	NN	mofetil	mofetil	mofetil	N	O
(	(	(	(	(	N	O
MMF	NNP	mmf	mmf	mmf	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
for	IN	for	for	for	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
liver	NN	liver	liver	liver	N	O
transplant	NN	transplant	transplant	transplant	Y	O
recipient	NN	recipient	recipient	recipi	N	O
was	VBD	was	wa	wa	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
dosage	NN	dosage	dosage	dosag	N	O
regimen	NNS	regimen	regimen	regimen	N	O
that	WDT	that	that	that	N	O
was	VBD	was	wa	wa	N	O
more	RBR	more	more	more	N	O
intensive	JJ	intensive	intensive	intens	N	O
than	IN	than	than	than	N	O
that	DT	that	that	that	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
kidney	NN	kidney	kidney	kidney	N	O
transplant	NN	transplant	transplant	transplant	Y	O
recipients	NNS	recipients	recipient	recipi	N	O
,	,	,	,	,	N	O
MMF	NNP	mmf	mmf	mmf	N	O
at	IN	at	at	at	N	O
doses	VBZ	doses	dos	dose	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Bacterial	NNP	bacterial	bacterial	bacteri	N	O
,	,	,	,	,	N	O
Mycobacterial	NNP	mycobacterial	mycobacterial	mycobacteri	N	O
,	,	,	,	,	N	O
Viral	NNP	viral	viral	viral	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Fungal	NNP	fungal	fungal	fungal	N	O
Infections	NNP	infections	infection	infect	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
infectious	JJ	infectious	infectious	infecti	N	B-AdverseReaction
etiology	NN	etiology	etiology	etiolog	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
clinical	JJ	clinical	clinical	clinic	N	O
assessment	NN	assessment	assessment	assess	N	O
by	IN	by	by	by	N	O
physicians	NNS	physicians	physician	physician	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
causative	JJ	causative	causative	caus	N	O
organisms	NNS	organisms	organism	organ	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
identified	VBN	identified	identified	identifi	N	O
when	WRB	when	when	when	N	O
provided	VBN	provided	provided	provid	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
physician	NN	physician	physician	physician	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
select	JJ	select	select	select	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
with	IN	with	with	with	N	O
identified	JJ	identified	identified	identifi	N	O
etiology	NN	etiology	etiology	etiolog	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Fungal	JJ	fungal	fungal	fungal	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
18%	CD	18%	18%	18%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
22%	CD	22%	22%	22%	N	O
receiving	VBG	receiving	receiving	receiv	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
,	,	,	,	,	N	O
primarily	RB	primarily	primarily	primarili	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
skin	VB	skin	skin	skin	N	B-AdverseReaction
and	CC	and	and	and	N	O
mucocutaneous	JJ	mucocutaneous	mucocutaneous	mucocutan	N	B-AdverseReaction
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

Tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
than	IN	than	than	than	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
through	IN	through	through	through	N	O
3	CD	3	3	3	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
but	CC	but	but	but	N	O
one	CD	one	one	one	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
patient	NN	patient	patient	patient	N	O
lived	VBD	lived	lived	live	N	O
in	IN	in	in	in	N	O
countries	NNS	countries	country	countri	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
high	JJ	high	high	high	N	O
prevalence	NN	prevalence	prevalence	preval	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Overall	JJ	overall	overall	overal	N	O
Infections	NNS	infections	infection	infect	N	B-AdverseReaction
and	CC	and	and	and	N	O
Select	NNP	select	select	select	N	O
Infections	NNP	infections	infection	infect	N	B-AdverseReaction
with	IN	with	with	with	N	O
Identified	NNP	identified	identified	identifi	N	O
Etiology	NNP	etiology	etiology	etiolog	N	O
by	IN	by	by	by	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Group	NNP	group	group	group	N	O
following	VBG	following	following	follow	N	O
One	CD	one	one	one	N	O
and	CC	and	and	and	N	O
Three	CD	three	three	three	N	O
Years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O

Up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
Year	VB	year	year	year	N	O
1	CD	1	1	1	N	O
Up	NNP	up	up	up	N	O
to	TO	to	to	to	N	O
Year	VB	year	year	year	N	O
3	CD	3	3	3	N	O

NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
Recommended	VBD	recommended	recommended	recommend	N	O
Regimen	NNP	regimen	regimen	regimen	N	O
N	NNP	n	n	n	N	O
401	CD	401	401	401	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Cyclosporine	NNP	cyclosporine	cyclosporine	cyclosporin	N	O
N	NNP	n	n	n	N	O
405	CD	405	405	405	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
Recommended	NNP	recommended	recommended	recommend	N	O
Regimen	NNP	regimen	regimen	regimen	N	O
N	NNP	n	n	n	N	O
401	CD	401	401	401	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Cyclosporine	NNP	cyclosporine	cyclosporine	cyclosporin	N	O
N	NNP	n	n	n	N	O
405	CD	405	405	405	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Studies	NNS	studies	study	studi	N	O

1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
designed	VBN	designed	designed	design	N	O
to	TO	to	to	to	N	O
support	VB	support	support	support	N	O
comparative	JJ	comparative	comparative	compar	N	O
claims	NNS	claims	claim	claim	N	O
for	IN	for	for	for	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
table	NN	table	table	tabl	N	O
.	.	.	.	.	N	O

Median	JJ	median	median	median	N	O
exposure	NN	exposure	exposure	exposur	N	O
in	IN	in	in	in	N	O
days	NNS	days	day	day	N	O
for	IN	for	for	for	N	O
pooled	JJ	pooled	pooled	pool	N	O
studies	NNS	studies	study	studi	N	O
:	:	:	:	:	N	O
1203	CD	1203	1203	1203	N	O
for	IN	for	for	for	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
and	CC	and	and	and	N	O
1163	CD	1163	1163	1163	N	O
for	IN	for	for	for	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O
?	.	?	?	?	N	O

All	DT	all	all	all	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
include	VBP	include	include	includ	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	I-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	I-AdverseReaction
,	,	,	,	,	N	O
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
organisms	NNS	organisms	organism	organ	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
infectious	JJ	infectious	infectious	infecti	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
causative	JJ	causative	causative	caus	N	O
organism	NN	organism	organism	organ	N	O
is	VBZ	is	is	is	N	O
reported	VBN	reported	reported	report	N	O
if	IN	if	if	if	N	O
specified	VBN	specified	specified	specifi	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
physician	NN	physician	physician	physician	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

S	VB	s	s	s	N	O
A	NNP	a	a	a	N	O
medically	RB	medically	medically	medic	N	O
important	JJ	important	important	import	N	O
event	NN	event	event	event	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	NN	threatening	threatening	threaten	N	O
or	CC	or	or	or	N	O
result	NN	result	result	result	N	O
in	IN	in	in	in	N	O
death	NN	death	death	death	Y	B-AdverseReaction
or	CC	or	or	or	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
of	IN	of	of	of	N	O
existing	VBG	existing	existing	exist	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
not	RB	not	not	not	N	O
meeting	VBG	meeting	meeting	meet	N	O
these	DT	these	these	these	N	O
criteria	NNS	criteria	criterion	criteria	N	O
are	VBP	are	are	are	N	O
considered	VBN	considered	considered	consid	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
serious	JJ	serious	serious	seriou	N	O
.	.	.	.	.	N	O

BK	NNP	bk	bk	bk	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
associated	VBN	associated	associated	associ	N	I-AdverseReaction
nephropathy	NN	nephropathy	nephropathy	nephropathi	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
6	CD	6	6	6	N	O
NULOJIX	JJ	nulojix	nulojix	nulojix	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
graft	JJ	graft	graft	graft	N	O
loss	NN	loss	loss	loss	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
6	CD	6	6	6	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
graft	JJ	graft	graft	graft	N	O
loss	NN	loss	loss	loss	N	O
)	)	)	)	)	N	O
by	IN	by	by	by	N	O
Year	$	year	year	year	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
were	VBD	were	were	were	N	O
non	JJ	non	non	non	N	B-Severity
-	:	-	-	-	N	I-Severity
serious	JJ	serious	serious	seriou	N	I-Severity
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O

infections	NNS	infections	infection	infect	N	B-AdverseReaction
?	.	?	?	?	N	O

287	CD	287	287	287	N	O
(	(	(	(	(	N	O
72	CD	72	72	72	N	O
)	)	)	)	)	N	O
299	CD	299	299	299	N	O
(	(	(	(	(	N	O
74	CD	74	74	74	N	O
)	)	)	)	)	N	O
329	CD	329	329	329	N	O
(	(	(	(	(	N	O
82	CD	82	82	82	N	O
)	)	)	)	)	N	O
327	CD	327	327	327	N	O
(	(	(	(	(	N	O
81	CD	81	81	81	N	O
)	)	)	)	)	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infectionsS	NN	infectionss	infection	infectionss	N	B-AdverseReaction
98	CD	98	98	98	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
)	)	)	)	)	N	O
113	CD	113	113	113	N	O
(	(	(	(	(	N	O
28	CD	28	28	28	N	O
)	)	)	)	)	N	O
144	CD	144	144	144	N	O
(	(	(	(	(	N	O
36	CD	36	36	36	N	O
)	)	)	)	)	N	O
157	CD	157	157	157	N	O
(	(	(	(	(	N	O
39	CD	39	39	39	N	O
)	)	)	)	)	N	O

CMV	NNP	cmv	cmv	cmv	N	I-AdverseReaction
44	CD	44	44	44	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
52	CD	52	52	52	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
53	CD	53	53	53	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
56	CD	56	56	56	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O

Polyoma	NNP	polyoma	polyoma	polyoma	N	I-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O

Herpes	$	herpes	herpes	herp	N	I-AdverseReaction
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
26	CD	26	26	26	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
55	CD	55	55	55	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

Tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
Reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CNS	NNP	cns	cns	cn	N	O

Following	VBG	following	following	follow	N	O
three	CD	three	three	three	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
cryptococcal	JJ	cryptococcal	cryptococcal	cryptococc	N	B-AdverseReaction
meningitis	NN	meningitis	meningitis	mening	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
401	CD	401	401	401	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
405	CD	405	405	405	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Six	CD	six	six	six	N	O
patients	NNS	patients	patient	patient	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
403	NNS	403	403	403	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimen	NNS	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
higher	JJR	higher	higher	higher	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
dosing	NN	dosing	dosing	dose	N	O
than	IN	than	than	than	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
developed	VBN	developed	developed	develop	N	O
CNS	NNP	cns	cns	cn	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
2	CD	2	2	2	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
cryptococcal	JJ	cryptococcal	cryptococcal	cryptococc	N	B-AdverseReaction
meningitis	NN	meningitis	meningitis	mening	Y	I-AdverseReaction
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
Chagas	NNP	chagas	chaga	chaga	N	B-AdverseReaction
encephalitis	NN	encephalitis	encephalitis	enceph	Y	I-AdverseReaction
with	IN	with	with	with	N	O
cryptococcal	JJ	cryptococcal	cryptococcal	cryptococc	N	B-AdverseReaction
meningitis	NN	meningitis	meningitis	mening	Y	I-AdverseReaction
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	B-AdverseReaction
aspergillosis	NN	aspergillosis	aspergillosis	aspergillosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
West	NNP	west	west	west	N	B-AdverseReaction
Nile	NNP	nile	nile	nile	N	I-AdverseReaction
encephalitis	NN	encephalitis	encephalitis	enceph	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
(	(	(	(	(	N	O
discussed	VBN	discussed	discussed	discuss	N	O
above	RB	above	above	abov	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Infusion	NN	infusion	infusion	infus	Y	O
Reactions	NNS	reactions	reaction	reaction	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	B-Negation
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
or	CC	or	or	or	N	O
drug	NN	drug	drug	drug	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
through	IN	through	through	through	N	O
three	CD	three	three	three	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Infusion	NNP	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
within	IN	within	within	within	N	O
one	CD	one	one	one	N	O
hour	NN	hour	hour	hour	N	O
of	IN	of	of	of	N	O
infusion	NN	infusion	infusion	infus	Y	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
,	,	,	,	,	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
rate	NN	rate	rate	rate	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
serious	JJ	serious	serious	seriou	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
through	IN	through	through	through	N	O
Year	NN	year	year	year	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
.	.	.	.	.	N	O

Proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	O

At	IN	at	at	at	N	O
Month	NNP	month	month	month	N	O
1	CD	1	1	1	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	B-Severity
proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
on	IN	on	on	on	N	O
urine	JJ	urine	urine	urin	N	O
dipstick	NN	dipstick	dipstick	dipstick	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
was	VBD	was	wa	wa	N	O
33%	CD	33%	33%	33%	N	O
(	(	(	(	(	N	O
130	CD	130	130	130	N	O
390	CD	390	390	390	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
28%	CD	28%	28%	28%	N	O
(	(	(	(	(	N	O
107	CD	107	107	107	N	O
384	CD	384	384	384	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	B-Severity
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
between	IN	between	between	between	N	O
one	CD	one	one	one	N	O
and	CC	and	and	and	N	O
three	CD	three	three	three	N	O
years	NNS	years	year	year	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
studies	NNS	studies	study	studi	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	O
differences	NNS	differences	difference	differ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
3	CD	3	3	3	N	B-Severity
proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
studies	NNS	studies	study	studi	N	O
)	)	)	)	)	N	O
at	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
time	NN	time	time	time	N	O
point	NN	point	point	point	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	B-Negation
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
4	CD	4	4	4	N	B-Severity
proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
early	JJ	early	early	earli	N	B-AdverseReaction
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	I-AdverseReaction
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

Antibodies	NNS	antibodies	antibody	antibodi	N	O
directed	VBN	directed	directed	direct	N	O
against	IN	against	against	against	N	O
the	DT	the	the	the	N	O
belatacept	NN	belatacept	belatacept	belatacept	N	O
molecule	NN	molecule	molecule	molecul	N	O
were	VBD	were	were	were	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
398	CD	398	398	398	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
212	CD	212	212	212	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
372	CD	372	372	372	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
immunogenicity	JJ	immunogenicity	immunogenicity	immunogen	N	O
assessment	NN	assessment	assessment	assess	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
receiving	VBG	receiving	receiving	receiv	N	O
belatacept	JJ	belatacept	belatacept	belatacept	N	O
treatment	NN	treatment	treatment	treatment	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
29	CD	29	29	29	N	O
patients	NNS	patients	patient	patient	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
belatacept	NN	belatacept	belatacept	belatacept	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
;	:	;	;	;	N	O
13	CD	13	13	13	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
modified	VBN	modified	modified	modifi	N	O
cytotoxic	NN	cytotoxic	cytotoxic	cytotox	N	O
T	NNP	t	t	t	N	O
-	:	-	-	-	N	O
lymphocyte	NN	lymphocyte	lymphocyte	lymphocyt	N	O
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
antigen	NN	antigen	antigen	antigen	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
CTLA	NNP	ctla	ctla	ctla	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Anti	NNP	anti	anti	anti	N	O
-	:	-	-	-	N	O
belatacept	NN	belatacept	belatacept	belatacept	N	O
antibody	NN	antibody	antibody	antibodi	N	O
titers	NNS	titers	titer	titer	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
increase	VB	increase	increase	increas	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
29	CD	29	29	29	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Eight	NNP	eight	eight	eight	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
developed	JJ	developed	developed	develop	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
titer	NN	titer	titer	titer	N	O
(	(	(	(	(	N	O
by	IN	by	by	by	N	O
dilution	NN	dilution	dilution	dilut	N	O
method	NN	method	method	method	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
8	CD	8	8	8	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
to	TO	to	to	to	N	O
80	CD	80	80	80	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
56	CD	56	56	56	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
negative	JJ	negative	negative	neg	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
reassessed	VBD	reassessed	reassessed	reassess	N	O
approximately	RB	approximately	approximately	approxim	N	O
7	CD	7	7	7	N	O
half	NN	half	half	half	N	O
-	:	-	-	-	N	O
lives	NNS	lives	life	live	N	O
after	IN	after	after	after	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
tested	VBD	tested	tested	test	N	O
antibody	NN	antibody	antibody	antibodi	N	O
positive	JJ	positive	positive	posit	N	O
.	.	.	.	.	N	O

Anti	NNP	anti	anti	anti	N	O
-	:	-	-	-	N	O
belatacept	NN	belatacept	belatacept	belatacept	N	O
antibody	NN	antibody	antibody	antibodi	N	O
development	NN	development	development	develop	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
altered	JJ	altered	altered	alter	N	O
clearance	NN	clearance	clearance	clearanc	N	O
of	IN	of	of	of	N	O
belatacept	NN	belatacept	belatacept	belatacept	N	O
.	.	.	.	.	N	O

Samples	NNS	samples	sample	sampl	N	O
from	IN	from	from	from	N	O
6	CD	6	6	6	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
confirmed	JJ	confirmed	confirmed	confirm	N	O
binding	VBG	binding	binding	bind	N	O
activity	NN	activity	activity	activ	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
modified	VBN	modified	modified	modifi	N	O
cytotoxic	NN	cytotoxic	cytotoxic	cytotox	N	O
T	NNP	t	t	t	N	O
-	:	-	-	-	N	O
lymphocyte	NN	lymphocyte	lymphocyte	lymphocyt	N	O
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
antigen	NN	antigen	antigen	antigen	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
CTLA	NNP	ctla	ctla	ctla	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
region	NN	region	region	region	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
belatacept	NN	belatacept	belatacept	belatacept	N	O
molecule	NN	molecule	molecule	molecul	N	O
were	VBD	were	were	were	N	O
assessed	VBN	assessed	assessed	assess	N	O
by	IN	by	by	by	N	O
an	DT	an	an	an	N	O
in	IN	in	in	in	N	O
vitro	NN	vitro	vitro	vitro	N	O
bioassay	NN	bioassay	bioassay	bioassay	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
6	CD	6	6	6	N	O
patients	NNS	patients	patient	patient	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
underreported	VBN	underreported	underreported	underreport	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
lack	VB	lack	lack	lack	N	O
of	IN	of	of	of	N	O
assay	JJ	assay	assay	assay	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
impact	NN	impact	impact	impact	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
belatacept	NN	belatacept	belatacept	belatacept	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
belatacept	IN	belatacept	belatacept	belatacept	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
)	)	)	)	)	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
determined	VBN	determined	determined	determin	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
test	NN	test	test	test	N	O
results	NNS	results	result	result	N	O
were	VBD	were	were	were	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
belatacept	VB	belatacept	belatacept	belatacept	N	O
in	IN	in	in	in	N	O
specific	JJ	specific	specific	specif	N	O
assays	NNS	assays	assay	assay	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
)	)	)	)	)	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
,	,	,	,	,	N	O
assay	VBP	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
belatacept	VB	belatacept	belatacept	belatacept	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O

New	NNP	new	new	new	N	O
-	:	-	-	-	N	O
Onset	NN	onset	onset	onset	N	O
Diabetes	VBZ	diabetes	diabetes	diabet	Y	O
After	IN	after	after	after	N	O
Transplantation	NN	transplantation	transplantation	transplant	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
new	JJ	new	new	new	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
onset	NN	onset	onset	onset	N	I-AdverseReaction
diabetes	NNS	diabetes	diabetes	diabet	Y	I-AdverseReaction
after	IN	after	after	after	N	I-AdverseReaction
transplantation	NN	transplantation	transplantation	transplant	N	I-AdverseReaction
(	(	(	(	(	N	O
NODAT	NNP	nodat	nodat	nodat	N	B-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
defined	VBN	defined	defined	defin	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
as	IN	as	a	as	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
agent	NN	agent	agent	agent	N	O
for	IN	for	for	for	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
or	CC	or	or	or	N	O
2	CD	2	2	2	N	O
fasting	VBG	fasting	fasting	fast	Y	O
plasma	NN	plasma	plasma	plasma	N	O
glucose	NN	glucose	glucose	glucos	Y	O
values	NNS	values	value	valu	N	O
126	CD	126	126	126	N	O
mg	NNS	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
(	(	(	(	(	N	O
7.0	CD	7.0	7.0	7.0	N	O
mmol	RB	mmol	mmol	mmol	N	O
L	NNP	l	l	l	N	O
)	)	)	)	)	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
,	,	,	,	,	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
304	CD	304	304	304	N	O
)	)	)	)	)	N	O
developed	VBN	developed	developed	develop	N	O
NODAT	NNP	nodat	nodat	nodat	N	B-AdverseReaction
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
end	NN	end	end	end	N	O
of	IN	of	of	of	N	O
one	CD	one	one	one	N	O
year	NN	year	year	year	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
10%	CD	10%	10%	10%	N	O
(	(	(	(	(	N	O
27	CD	27	27	27	N	O
280	CD	280	280	280	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
end	NN	end	end	end	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
third	JJ	third	third	third	N	O
year	NN	year	year	year	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
NODAT	NNP	nodat	nodat	nodat	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
8%	CD	8%	8%	8%	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
304	CD	304	304	304	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
and	CC	and	and	and	N	O
10%	CD	10%	10%	10%	N	O
(	(	(	(	(	N	O
29	CD	29	29	29	N	O
280	CD	280	280	280	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	O

Blood	NNP	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
and	CC	and	and	and	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
antihypertensive	JJ	antihypertensive	antihypertensive	antihypertens	N	O
medications	NNS	medications	medication	medic	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
Studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

By	IN	by	by	by	N	O
Year	NNP	year	year	year	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
antihypertensive	JJ	antihypertensive	antihypertensive	antihypertens	N	O
medications	NNS	medications	medication	medic	N	O
were	VBD	were	were	were	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
85%	CD	85%	85%	85%	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
92%	CD	92%	92%	92%	N	O
of	IN	of	of	of	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
one	CD	one	one	one	N	O
year	NN	year	year	year	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
,	,	,	,	,	N	O
systolic	JJ	systolic	systolic	systol	N	O
blood	NN	blood	blood	blood	N	O
pressures	NNS	pressures	pressure	pressur	N	O
were	VBD	were	were	were	N	O
8	CD	8	8	8	N	O
mmHg	NNS	mmhg	mmhg	mmhg	N	O
lower	JJR	lower	lower	lower	N	O
and	CC	and	and	and	N	O
diastolic	JJ	diastolic	diastolic	diastol	N	O
blood	NN	blood	blood	blood	N	O
pressures	NNS	pressures	pressure	pressur	N	O
were	VBD	were	were	were	N	O
3	CD	3	3	3	N	O
mmHg	NNS	mmhg	mmhg	mmhg	N	O
lower	JJR	lower	lower	lower	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
three	CD	three	three	three	N	O
years	NNS	years	year	year	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
,	,	,	,	,	N	O
systolic	JJ	systolic	systolic	systol	N	O
blood	NN	blood	blood	blood	N	O
pressures	NNS	pressures	pressure	pressur	N	O
were	VBD	were	were	were	N	O
6	CD	6	6	6	N	O
mmHg	NNS	mmhg	mmhg	mmhg	N	O
lower	JJR	lower	lower	lower	N	O
and	CC	and	and	and	N	O
diastolic	JJ	diastolic	diastolic	diastol	N	O
blood	NN	blood	blood	blood	N	O
pressures	NNS	pressures	pressure	pressur	N	O
were	VBD	were	were	were	N	O
3	CD	3	3	3	N	O
mmHg	NNS	mmhg	mmhg	mmhg	N	O
lower	JJR	lower	lower	lower	N	O
in	IN	in	in	in	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
cyclosporine	VB	cyclosporine	cyclosporine	cyclosporin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
32%	CD	32%	32%	32%	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
37%	CD	37%	37%	37%	N	O
of	IN	of	of	of	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	O

Mean	JJ	mean	mean	mean	N	O
values	NNS	values	value	valu	N	O
of	IN	of	of	of	N	O
total	JJ	total	total	total	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
,	,	,	,	,	N	O
HDL	NNP	hdl	hdl	hdl	Y	O
,	,	,	,	,	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
Studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
one	CD	one	one	one	N	O
year	NN	year	year	year	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
these	DT	these	these	these	N	O
values	NNS	values	value	valu	N	O
were	VBD	were	were	were	N	O
183	CD	183	183	183	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
102	CD	102	102	102	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
151	CD	151	151	151	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
401	CD	401	401	401	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
and	CC	and	and	and	N	O
196	CD	196	196	196	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
48	CD	48	48	48	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
108	CD	108	108	108	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
195	CD	195	195	195	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
405	CD	405	405	405	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
three	CD	three	three	three	N	O
years	NNS	years	year	year	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
total	JJ	total	total	total	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
,	,	,	,	,	N	O
HDL	NNP	hdl	hdl	hdl	Y	O
,	,	,	,	,	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O
were	VBD	were	were	were	N	O
176	CD	176	176	176	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
49	CD	49	49	49	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
141	CD	141	141	141	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
193	CD	193	193	193	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
48	CD	48	48	48	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
106	CD	106	106	106	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
180	CD	180	180	180	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
in	IN	in	in	in	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
lower	JJR	lower	lower	lower	N	O
mean	JJ	mean	mean	mean	N	O
triglyceride	NN	triglyceride	triglyceride	triglycerid	N	O
values	NNS	values	value	valu	N	O
in	IN	in	in	in	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
one	CD	one	one	one	N	O
and	CC	and	and	and	N	O
three	CD	three	three	three	N	O
years	NNS	years	year	year	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
recommended	VBD	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
or	CC	or	or	or	N	O
cyclosporine	VB	cyclosporine	cyclosporine	cyclosporin	N	O
control	NN	control	control	control	N	O
regimen	NNS	regimen	regimen	regimen	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
through	IN	through	through	through	N	O
three	CD	three	three	three	N	O
years	NNS	years	year	year	N	O
are	VBP	are	are	are	N	O
summarized	VBN	summarized	summarized	summar	N	O
by	IN	by	by	by	N	O
preferred	JJ	preferred	preferred	prefer	N	O
term	NN	term	term	term	N	O
in	IN	in	in	in	N	O
decreasing	VBG	decreasing	decreasing	decreas	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
frequency	NN	frequency	frequency	frequenc	N	O
within	IN	within	within	within	N	O
Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Either	NNP	either	either	either	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
Recommended	NNP	recommended	recommended	recommend	N	O
Regimen	NNP	regimen	regimen	regimen	N	O
or	CC	or	or	or	N	O
Control	NNP	control	control	control	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
Through	IN	through	through	through	N	O
Three	CD	three	three	three	N	O
Years	NNS	years	year	year	N	O
,	,	,	,	,	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
Recommended	NNP	recommended	recommended	recommend	N	O
Regimen	NNP	regimen	regimen	regimen	N	O
N	NNP	n	n	n	N	O
401	CD	401	401	401	N	O
Cyclosporine	NNP	cyclosporine	cyclosporine	cyclosporin	N	O
N	NNP	n	n	n	N	O
405	CD	405	405	405	N	O

All	DT	all	all	all	N	O

randomized	VBN	randomized	randomized	random	N	O
and	CC	and	and	and	N	O
transplanted	VBN	transplanted	transplanted	transplant	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
designed	VBN	designed	designed	design	N	O
to	TO	to	to	to	N	O
support	VB	support	support	support	N	O
comparative	JJ	comparative	comparative	compar	N	O
claims	NNS	claims	claim	claim	N	O
for	IN	for	for	for	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
table	NN	table	table	tabl	N	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	O

and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
37	CD	37	37	37	N	O
36	CD	36	36	36	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
15	CD	15	15	15	N	O
16	CD	16	16	16	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
13	CD	13	13	13	N	O
16	CD	16	16	16	N	O

Cytomegalovirus	NNP	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
12	CD	12	12	12	N	O
12	CD	12	12	12	N	O

Influenza	NNP	influenza	influenza	influenza	Y	B-AdverseReaction
11	CD	11	11	11	N	O
8	CD	8	8	8	N	O

Bronchitis	NNP	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
10	CD	10	10	10	N	O
7	CD	7	7	7	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
39	CD	39	39	39	N	O
36	CD	36	36	36	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
33	CD	33	33	33	N	O
35	CD	35	35	35	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
24	CD	24	24	24	N	O
27	CD	27	27	27	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
22	CD	22	22	22	N	O
20	CD	20	20	20	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
19	CD	19	19	19	N	O
16	CD	16	16	16	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
9	CD	9	9	9	N	O
10	CD	10	10	10	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hyperkalemia	NNP	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
20	CD	20	20	20	N	O
20	CD	20	20	20	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
21	CD	21	21	21	N	O
14	CD	14	14	14	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
13	CD	13	13	13	N	O

Dyslipidemia	NNP	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
24	CD	24	24	24	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
16	CD	16	16	16	N	O
17	CD	17	17	17	N	O

Hypocalcemia	NNP	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
11	CD	11	11	11	N	O

Hypercholesterolemia	NNP	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
11	CD	11	11	11	N	O

Hypomagnesemia	NNP	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	B-AdverseReaction
7	CD	7	7	7	N	O
10	CD	10	10	10	N	O

Hyperuricemia	NNP	hyperuricemia	hyperuricemia	hyperuricemia	Y	B-AdverseReaction
5	CD	5	5	5	N	O
12	CD	12	12	12	N	O

Procedural	JJ	procedural	procedural	procedur	N	O
Complications	NNS	complications	complication	complic	N	O

Graft	NNP	graft	graft	graft	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
25	CD	25	25	25	N	O
34	CD	34	34	34	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	VBD	edema	edema	edema	Y	I-AdverseReaction
34	CD	34	34	34	N	O
42	CD	42	42	42	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
28	CD	28	28	28	N	O
26	CD	26	26	26	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
45	CD	45	45	45	N	O
44	CD	44	44	44	N	O

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
20	CD	20	20	20	N	O
23	CD	23	23	23	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
Urinary	NNP	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hematuria	NNP	hematuria	hematuria	hematuria	Y	B-AdverseReaction
16	CD	16	16	16	N	O
18	CD	18	18	18	N	O

Proteinuria	NNP	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
16	CD	16	16	16	N	O
12	CD	12	12	12	N	O

Dysuria	NNP	dysuria	dysuria	dysuria	Y	B-AdverseReaction
11	CD	11	11	11	N	O
11	CD	11	11	11	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
tubular	JJ	tubular	tubular	tubular	N	I-AdverseReaction
necrosis	NN	necrosis	necrosis	necrosi	Y	I-AdverseReaction
9	CD	9	9	9	N	O
13	CD	13	13	13	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
32	CD	32	32	32	N	O
37	CD	37	37	37	N	O

Hypotension	NNP	hypotension	hypotension	hypotens	Y	B-AdverseReaction
18	CD	18	18	18	N	O
12	CD	12	12	12	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
24	CD	24	24	24	N	O
18	CD	18	18	18	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
12	CD	12	12	12	N	O
15	CD	15	15	15	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Blood	NNP	blood	blood	blood	N	B-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
15	CD	15	15	15	N	O
20	CD	20	20	20	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
17	CD	17	17	17	N	O
13	CD	13	13	13	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
13	CD	13	13	13	N	O
13	CD	13	13	13	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
21	CD	21	21	21	N	O
18	CD	18	18	18	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
9	CD	9	9	9	N	O
10	CD	10	10	10	N	O

Tremor	NNP	tremor	tremor	tremor	Y	B-AdverseReaction
8	CD	8	8	8	N	O
17	CD	17	17	17	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Acne	NNP	acne	acne	acn	Y	B-AdverseReaction
8	CD	8	8	8	N	O
11	CD	11	11	11	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
15	CD	15	15	15	N	O
18	CD	18	18	18	N	O

Anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
10	CD	10	10	10	N	O
11	CD	11	11	11	N	O

Selected	VBN	selected	selected	select	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
from	IN	from	from	from	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
either	DT	either	either	either	N	O
regimen	NNS	regimen	regimen	regimen	N	O
through	IN	through	through	through	N	O
three	CD	three	three	three	N	O
years	NNS	years	year	year	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
are	VBP	are	are	are	N	O
listed	VBN	listed	listed	list	N	O
below	IN	below	below	below	N	O
:	:	:	:	:	N	O

Immune	NN	immune	immune	immun	N	O

System	NN	system	system	system	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Guillain	NNP	guillain	guillain	guillain	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Barre	NNP	barre	barre	barr	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
see	VB	see	see	see	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
aphthous	JJ	aphthous	aphthous	aphthou	N	B-AdverseReaction
stomatitis	NN	stomatitis	stomatitis	stomat	Y	I-AdverseReaction

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
Poisoning	NNP	poisoning	poisoning	poison	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Procedural	JJ	procedural	procedural	procedur	N	O
Complications	NNS	complications	complication	complic	N	O
:	:	:	:	:	N	O
chronic	NN	chronic	chronic	chronic	N	B-AdverseReaction
allograft	NN	allograft	allograft	allograft	N	I-AdverseReaction
nephropathy	NN	nephropathy	nephropathy	nephropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
complications	NNS	complications	complication	complic	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
transplanted	JJ	transplanted	transplanted	transplant	N	I-AdverseReaction
kidney	NN	kidney	kidney	kidney	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
wound	NN	wound	wound	wound	Y	B-AdverseReaction
dehiscence	NN	dehiscence	dehiscence	dehisc	N	I-AdverseReaction
,	,	,	,	,	N	O
arteriovenous	JJ	arteriovenous	arteriovenous	arterioven	N	B-AdverseReaction
fistula	NN	fistula	fistula	fistula	Y	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
Urinary	JJ	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
artery	NN	artery	artery	arteri	N	I-AdverseReaction
stenosis	NN	stenosis	stenosis	stenosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
incontinence	NN	incontinence	incontinence	incontin	Y	I-AdverseReaction
,	,	,	,	,	N	O
hydronephrosis	NN	hydronephrosis	hydronephrosis	hydronephrosi	Y	B-AdverseReaction

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	B-AdverseReaction
,	,	,	,	,	N	O
lymphocele	NN	lymphocele	lymphocele	lymphocel	Y	B-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
musculoskeletal	NN	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
POST	NNP	post	post	post	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
TRANSPLANT	NNP	transplant	transplant	transplant	Y	I-AdverseReaction
LYMPHOPROLIFERATIVE	NNP	lymphoproliferative	lymphoproliferative	lymphoprolif	N	I-AdverseReaction
DISORDER	NNP	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
OTHER	NNP	other	other	other	N	O
MALIGNANCIES	NNP	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
AND	NNP	and	and	and	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
INFECTIONS	NNP	infections	infection	infect	N	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
POST	NNP	post	post	post	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
TRANSPLANT	NNP	transplant	transplant	transplant	Y	I-AdverseReaction
LYMPHOPROLIFERATIVE	NNP	lymphoproliferative	lymphoproliferative	lymphoprolif	N	I-AdverseReaction
DISORDER	NNP	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
OTHER	NNP	other	other	other	N	O
MALIGNANCIES	NNP	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
AND	NNP	and	and	and	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
INFECTIONS	NNP	infections	infection	infect	N	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Increased	VBD	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
developing	VBG	developing	developing	develop	N	O
post	NN	post	post	post	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
transplant	NN	transplant	transplant	transplant	Y	I-AdverseReaction
lymphoproliferative	JJ	lymphoproliferative	lymphoproliferative	lymphoprolif	N	I-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
involving	VBG	involving	involving	involv	N	O
the	DT	the	the	the	N	O
central	JJ	central	central	central	N	O
nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
(	(	(	(	(	N	O
CNS	NNP	cns	cns	cn	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Recipients	NNS	recipients	recipient	recipi	N	O
without	IN	without	without	without	N	O
immunity	NN	immunity	immunity	immun	N	O
to	TO	to	to	to	N	O
Epstein	NNP	epstein	epstein	epstein	N	O
-	:	-	-	-	N	O
Barr	NNP	barr	barr	barr	N	O
virus	NN	virus	virus	viru	N	O
(	(	(	(	(	N	O
EBV	NNP	ebv	ebv	ebv	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
particularly	RB	particularly	particularly	particularli	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
;	:	;	;	;	N	O
therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
only	RB	only	only	onli	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
in	IN	in	in	in	N	O
transplant	JJ	transplant	transplant	transplant	Y	O
recipients	NNS	recipients	recipient	recipi	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seronegative	JJ	seronegative	seronegative	seroneg	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
unknown	JJ	unknown	unknown	unknown	N	O
EBV	NNP	ebv	ebv	ebv	N	O
serostatus	NN	serostatus	serostatus	serostatu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Only	RB	only	only	onli	N	O
physicians	NNS	physicians	physician	physician	N	O
experienced	VBD	experienced	experienced	experienc	N	O
in	IN	in	in	in	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
kidney	NN	kidney	kidney	kidney	N	O
transplant	NN	transplant	transplant	transplant	Y	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
prescribe	VB	prescribe	prescribe	prescrib	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
managed	VBN	managed	managed	manag	N	O
in	IN	in	in	in	N	O
facilities	NNS	facilities	facility	facil	N	O
equipped	VBN	equipped	equipped	equip	N	O
and	CC	and	and	and	N	O
staffed	VBN	staffed	staffed	staf	N	O
with	IN	with	with	with	N	O
adequate	JJ	adequate	adequate	adequ	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
and	CC	and	and	and	N	O
supportive	JJ	supportive	supportive	support	N	O
medical	JJ	medical	medical	medic	N	O
resources	NNS	resources	resource	resourc	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
physician	NN	physician	physician	physician	N	O
responsible	JJ	responsible	responsible	respons	N	O
for	IN	for	for	for	N	O
maintenance	NN	maintenance	maintenance	mainten	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
complete	JJ	complete	complete	complet	N	O
information	NN	information	information	inform	N	O
requisite	NN	requisite	requisite	requisit	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
susceptibility	NN	susceptibility	susceptibility	suscept	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
possible	JJ	possible	possible	possibl	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
from	IN	from	from	from	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
liver	NN	liver	liver	liver	N	O
transplant	NN	transplant	transplant	transplant	Y	O
patients	NNS	patients	patient	patient	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
graft	NN	graft	graft	graft	N	O
loss	NN	loss	loss	loss	N	O
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
POST	NNP	post	post	post	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
TRANSPLANT	NNP	transplant	transplant	transplant	Y	I-AdverseReaction
LYMPHOPROLIFERATIVE	NNP	lymphoproliferative	lymphoproliferative	lymphoprolif	N	I-AdverseReaction
DISORDER	NNP	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
OTHER	NNP	other	other	other	N	O
MALIGNANCIES	NNP	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
AND	NNP	and	and	and	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
INFECTIONS	NNP	infections	infection	infect	N	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
developing	VBG	developing	developing	develop	N	O
post	NN	post	post	post	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
transplant	NN	transplant	transplant	transplant	Y	I-AdverseReaction
lymphoproliferative	JJ	lymphoproliferative	lymphoproliferative	lymphoprolif	N	I-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
involving	VBG	involving	involving	involv	N	O
the	DT	the	the	the	N	O
central	JJ	central	central	central	N	O
nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
(	(	(	(	(	N	O
CNS	NNP	cns	cns	cn	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Recipients	NNS	recipients	recipient	recipi	N	O
without	IN	without	without	without	N	O
immunity	NN	immunity	immunity	immun	N	O
to	TO	to	to	to	N	O
Epstein	NNP	epstein	epstein	epstein	N	O
-	:	-	-	-	N	O
Barr	NNP	barr	barr	barr	N	O
virus	NN	virus	virus	viru	N	O
(	(	(	(	(	N	O
EBV	NNP	ebv	ebv	ebv	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
particularly	RB	particularly	particularly	particularli	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
;	:	;	;	;	N	O
therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
only	RB	only	only	onli	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
in	IN	in	in	in	N	O
transplant	JJ	transplant	transplant	transplant	Y	O
recipients	NNS	recipients	recipient	recipi	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seronegative	JJ	seronegative	seronegative	seroneg	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
unknown	JJ	unknown	unknown	unknown	N	O
serostatus	NN	serostatus	serostatus	serostatu	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
Only	RB	only	only	onli	N	O
physicians	VBZ	physicians	physician	physician	N	O
experienced	VBN	experienced	experienced	experienc	N	O
in	IN	in	in	in	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
kidney	NN	kidney	kidney	kidney	N	O
transplant	NN	transplant	transplant	transplant	Y	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
prescribe	VB	prescribe	prescribe	prescrib	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
Increased	VBD	increased	increased	increas	N	B-AdverseReaction
susceptibility	NN	susceptibility	susceptibility	suscept	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
possible	JJ	possible	possible	possibl	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
from	IN	from	from	from	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
liver	NN	liver	liver	liver	N	O
transplant	NN	transplant	transplant	transplant	Y	O
patients	NNS	patients	patient	patient	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
graft	NN	graft	graft	graft	N	O
loss	NN	loss	loss	loss	N	O
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Post	NNP	post	post	post	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Transplant	NN	transplant	transplant	transplant	Y	I-AdverseReaction
Lymphoproliferative	JJ	lymphoproliferative	lymphoproliferative	lymphoprolif	N	I-AdverseReaction
Disorder	NNP	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
,	,	,	,	,	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
involving	VBG	involving	involving	involv	N	O
the	DT	the	the	the	N	O
CNS	NNP	cns	cns	cn	N	O
;	:	;	;	;	N	O
monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
,	,	,	,	,	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
behavioral	JJ	behavioral	behavioral	behavior	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Other	JJ	other	other	other	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
:	:	:	:	:	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	B-DrugClass
;	:	;	;	;	N	O
appears	VBZ	appears	appears	appear	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
intensity	NN	intensity	intensity	intens	N	O
and	CC	and	and	and	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
prolonged	VBD	prolonged	prolonged	prolong	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
UV	NNP	uv	uv	uv	N	O
light	NN	light	light	light	N	O
and	CC	and	and	and	N	O
sunlight	NN	sunlight	sunlight	sunlight	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Progressive	JJ	progressive	progressive	progress	N	B-AdverseReaction
Multifocal	NNP	multifocal	multifocal	multifoc	N	I-AdverseReaction
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
;	:	;	;	;	N	O
consider	VB	consider	consider	consid	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
reporting	VBG	reporting	reporting	report	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
,	,	,	,	,	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
behavioral	JJ	behavioral	behavioral	behavior	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

Recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
exceeded	VBN	exceeded	exceeded	exceed	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
:	:	:	:	:	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	B-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
,	,	,	,	,	N	O
fungal	JJ	fungal	fungal	fungal	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
protozoal	NN	protozoal	protozoal	protozo	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
and	CC	and	and	and	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
were	VBD	were	were	were	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Polyoma	NNP	polyoma	polyoma	polyoma	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
associated	VBN	associated	associated	associ	N	I-AdverseReaction
nephropathy	JJ	nephropathy	nephropathy	nephropathi	Y	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
kidney	VB	kidney	kidney	kidney	N	B-AdverseReaction
graft	JJ	graft	graft	graft	N	I-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
;	:	;	;	;	N	O
consider	VB	consider	consider	consid	N	O
reduction	NN	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
.	.	.	.	.	N	O

Evaluate	NNP	evaluate	evaluate	evalu	N	O
for	IN	for	for	for	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Cytomegalovirus	NNP	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	O
and	CC	and	and	and	N	O
pneumocystis	NN	pneumocystis	pneumocystis	pneumocysti	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
are	VBP	are	are	are	N	O
recommended	VBN	recommended	recommended	recommend	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Liver	NNP	liver	liver	liver	N	O
transplant	NN	transplant	transplant	transplant	Y	O
:	:	:	:	:	N	O
use	NN	use	use	use	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
Rejection	NNP	rejection	rejection	reject	N	I-AdverseReaction
and	CC	and	and	and	N	O
Graft	NNP	graft	graft	graft	N	I-AdverseReaction
Loss	NNP	loss	loss	loss	N	I-AdverseReaction
with	IN	with	with	with	N	O
Corticosteroid	NNP	corticosteroid	corticosteroid	corticosteroid	N	O
Minimization	NNP	minimization	minimization	minim	N	O
:	:	:	:	:	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
utilization	NN	utilization	utilization	util	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
experience	NN	experience	experience	experi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
,	,	,	,	,	N	O
5.7	CD	5.7	5.7	5.7	N	O
,	,	,	,	,	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O

Immunizations	NNS	immunizations	immunization	immun	N	O
:	:	:	:	:	N	O
avoid	NN	avoid	avoid	avoid	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Post	NN	post	post	post	N	O

-	:	-	-	-	N	O
Transplant	NN	transplant	transplant	transplant	Y	O
Lymphoproliferative	JJ	lymphoproliferative	lymphoproliferative	lymphoprolif	N	O
Disorder	NN	disorder	disorder	disord	N	O

NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
have	VBP	have	have	have	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
developing	VBG	developing	developing	develop	N	O
post	NN	post	post	post	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
transplant	NN	transplant	transplant	transplant	Y	I-AdverseReaction
lymphoproliferative	JJ	lymphoproliferative	lymphoproliferative	lymphoprolif	N	I-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
involving	VBG	involving	involving	involv	N	O
the	DT	the	the	the	N	O
CNS	NNP	cns	cns	cn	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
-	:	-	-	-	N	O
based	VBN	based	based	base	N	O
regimen	NNS	regimen	regimen	regimen	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

As	IN	as	a	as	N	O
the	DT	the	the	the	N	O
total	JJ	total	total	total	N	O
burden	NN	burden	burden	burden	N	O
of	IN	of	of	of	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	O
factor	NN	factor	factor	factor	N	O
for	IN	for	for	for	N	O
PTLD	NNP	ptld	ptld	ptld	N	O
,	,	,	,	,	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
dosing	NN	dosing	dosing	dose	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
and	CC	and	and	and	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
agents	NNS	agents	agent	agent	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
consider	VB	consider	consider	consid	N	O
PTLD	NNP	ptld	ptld	ptld	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
reporting	VBG	reporting	reporting	report	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
,	,	,	,	,	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
behavioral	JJ	behavioral	behavioral	behavior	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

EBV	NNP	ebv	ebv	ebv	N	O
Serostatus	NNP	serostatus	serostatus	serostatu	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seronegative	JJ	seronegative	seronegative	seroneg	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
are	VBP	are	are	are	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
having	VBG	having	having	have	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
acquired	VBN	acquired	acquired	acquir	N	O
immunity	NN	immunity	immunity	immun	N	O
shown	VBN	shown	shown	shown	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
IgG	NNP	igg	igg	igg	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
viral	JJ	viral	viral	viral	N	O
capsid	NN	capsid	capsid	capsid	N	O
antigen	NN	antigen	antigen	antigen	N	O
(	(	(	(	(	N	O
VCA	NNP	vca	vca	vca	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
EBV	NNP	ebv	ebv	ebv	N	O
nuclear	JJ	nuclear	nuclear	nuclear	N	O
antigen	NN	antigen	antigen	antigen	N	O
(	(	(	(	(	N	O
EBNA	NNP	ebna	ebna	ebna	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Epstein	NNP	epstein	epstein	epstein	N	O
-	:	-	-	-	N	O
Barr	NNP	barr	barr	barr	N	O
virus	NN	virus	virus	viru	N	O
serology	NN	serology	serology	serolog	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
ascertained	VBN	ascertained	ascertained	ascertain	N	O
before	IN	before	before	befor	N	O
starting	VBG	starting	starting	start	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
only	RB	only	only	onli	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
should	MD	should	should	should	N	O
receive	VB	receive	receive	receiv	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
.	.	.	.	.	N	O

Transplant	JJ	transplant	transplant	transplant	Y	O
recipients	NNS	recipients	recipient	recipi	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seronegative	JJ	seronegative	seronegative	seroneg	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
unknown	JJ	unknown	unknown	unknown	N	O
serostatus	NN	serostatus	serostatus	serostatu	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
receive	VB	receive	receive	receiv	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
and	CC	and	and	and	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Risk	NN	risk	risk	risk	N	O
Factors	NNS	factors	factor	factor	N	O

Other	JJ	other	other	other	N	O
known	VBN	known	known	known	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
PTLD	NNP	ptld	ptld	ptld	N	O
include	VBP	include	include	includ	N	O
cytomegalovirus	NN	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	O
(	(	(	(	(	N	O
CMV	NNP	cmv	cmv	cmv	N	O
)	)	)	)	)	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
T	NNP	t	t	t	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
-	:	-	-	-	N	O
depleting	NN	depleting	depleting	deplet	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

T	NNP	t	t	t	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
-	:	-	-	-	N	O
depleting	VBG	depleting	depleting	deplet	N	O
therapies	NNS	therapies	therapy	therapi	N	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
acute	JJ	acute	acute	acut	N	O
rejection	NN	rejection	rejection	reject	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
.	.	.	.	.	N	O

CMV	NNP	cmv	cmv	cmv	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
and	CC	and	and	and	N	O
CMV	NNP	cmv	cmv	cmv	N	O
seronegative	NN	seronegative	seronegative	seroneg	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
PTLD	NNP	ptld	ptld	ptld	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
and	CC	and	and	and	N	O
CMV	NNP	cmv	cmv	cmv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Since	IN	since	since	sinc	N	O
CMV	NNP	cmv	cmv	cmv	N	O
seronegative	JJ	seronegative	seronegative	seroneg	N	O
patients	NNS	patients	patient	patient	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
CMV	NNP	cmv	cmv	cmv	N	O
disease	NN	disease	disease	diseas	N	O
(	(	(	(	(	N	O
a	DT	a	a	a	N	O
known	VBN	known	known	known	N	O
risk	NN	risk	risk	risk	N	O
factor	NN	factor	factor	factor	N	O
for	IN	for	for	for	N	O
PTLD	NNP	ptld	ptld	ptld	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
CMV	NNP	cmv	cmv	cmv	N	O
serology	NN	serology	serology	serolog	N	O
for	IN	for	for	for	N	O
PTLD	NNP	ptld	ptld	ptld	N	O
remains	VBZ	remains	remains	remain	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
determined	VBN	determined	determined	determin	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
findings	NNS	findings	finding	find	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
when	WRB	when	when	when	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Management	NNP	management	management	manag	N	O
of	IN	of	of	of	N	O
Immunosuppression	NNP	immunosuppression	immunosuppression	immunosuppress	Y	O

Only	RB	only	only	onli	N	O
physicians	NNS	physicians	physician	physician	N	O
experienced	VBD	experienced	experienced	experienc	N	O
in	IN	in	in	in	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
systemic	JJ	systemic	systemic	system	N	O
immunosuppressant	JJ	immunosuppressant	immunosuppressant	immunosuppress	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
should	MD	should	should	should	N	O
prescribe	VB	prescribe	prescribe	prescrib	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
managed	VBN	managed	managed	manag	N	O
in	IN	in	in	in	N	O
facilities	NNS	facilities	facility	facil	N	O
equipped	VBN	equipped	equipped	equip	N	O
and	CC	and	and	and	N	O
staffed	VBN	staffed	staffed	staf	N	O
with	IN	with	with	with	N	O
adequate	JJ	adequate	adequate	adequ	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
and	CC	and	and	and	N	O
supportive	JJ	supportive	supportive	support	N	O
medical	JJ	medical	medical	medic	N	O
resources	NNS	resources	resource	resourc	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
physician	NN	physician	physician	physician	N	O
responsible	JJ	responsible	responsible	respons	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
maintenance	NN	maintenance	maintenance	mainten	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
complete	JJ	complete	complete	complet	N	O
information	NN	information	information	inform	N	O
requisite	NN	requisite	requisite	requisit	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
]	NNP	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Other	JJ	other	other	other	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	O

Patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
skin	NN	skin	skin	skin	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
sunlight	VB	sunlight	sunlight	sunlight	N	O
and	CC	and	and	and	N	O
ultraviolet	VB	ultraviolet	ultraviolet	ultraviolet	N	O
(	(	(	(	(	N	O
UV	NNP	uv	uv	uv	N	O
)	)	)	)	)	N	O
light	NN	light	light	light	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
limited	VBN	limited	limited	limit	N	O
by	IN	by	by	by	N	O
wearing	VBG	wearing	wearing	wear	N	O
protective	JJ	protective	protective	protect	N	O
clothing	NN	clothing	clothing	cloth	N	O
and	CC	and	and	and	N	O
using	VBG	using	using	use	N	O
a	DT	a	a	a	N	O
sunscreen	NN	sunscreen	sunscreen	sunscreen	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
high	JJ	high	high	high	N	O
protection	NN	protection	protection	protect	N	O
factor	NN	factor	factor	factor	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Progressive	JJ	progressive	progressive	progress	N	O
Multifocal	NNP	multifocal	multifocal	multifoc	N	O
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O

Progressive	JJ	progressive	progressive	progress	N	O
multifocal	JJ	multifocal	multifocal	multifoc	N	O
leukoencephalopathy	NN	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
an	DT	an	an	an	N	O
often	RB	often	often	often	N	O
rapidly	RB	rapidly	rapidly	rapidli	N	O
progressive	JJ	progressive	progressive	progress	N	O
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	O
infection	NN	infection	infection	infect	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
CNS	NNP	cns	cns	cn	N	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
caused	VBN	caused	caused	caus	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
JC	NNP	jc	jc	jc	N	O
virus	NN	virus	virus	viru	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
human	JJ	human	human	human	N	O
polyoma	NN	polyoma	polyoma	polyoma	N	O
virus	NN	virus	virus	viru	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
,	,	,	,	,	N	O
two	CD	two	two	two	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
doses	NNS	doses	dos	dose	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
regimen	NNS	regimen	regimen	regimen	N	O
,	,	,	,	,	N	O
along	IN	along	along	along	N	O
with	IN	with	with	with	N	O
mycophenolate	NN	mycophenolate	mycophenolate	mycophenol	N	O
mofetil	NN	mofetil	mofetil	mofetil	N	O
(	(	(	(	(	N	O
MMF	NNP	mmf	mmf	mmf	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
;	:	;	;	;	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
kidney	NN	kidney	kidney	kidney	N	O
transplant	NN	transplant	transplant	transplant	Y	O
recipient	NN	recipient	recipient	recipi	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
second	JJ	second	second	second	N	O
case	NN	case	case	case	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
liver	NN	liver	liver	liver	N	O
transplant	NN	transplant	transplant	transplant	Y	O
recipient	NN	recipient	recipient	recipi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

As	IN	as	a	as	N	O
PML	NNP	pml	pml	pml	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
high	JJ	high	high	high	N	O
levels	NNS	levels	level	level	N	O
of	IN	of	of	of	N	O
overall	JJ	overall	overall	overal	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
and	CC	and	and	and	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressives	NNS	immunosuppressives	immunosuppressive	immunosuppress	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
MMF	NNP	mmf	mmf	mmf	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
exceeded	VBN	exceeded	exceeded	exceed	N	O
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
consider	VB	consider	consider	consid	N	O
PML	NNP	pml	pml	pml	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
differential	JJ	differential	differential	differenti	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
,	,	,	,	,	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
behavioral	JJ	behavioral	behavioral	behavior	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

PML	NNP	pml	pml	pml	N	O
is	VBZ	is	is	is	N	O
usually	RB	usually	usually	usual	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
by	IN	by	by	by	N	O
brain	NN	brain	brain	brain	N	O
imaging	NN	imaging	imaging	imag	N	O
,	,	,	,	,	N	O
cerebrospinal	JJ	cerebrospinal	cerebrospinal	cerebrospin	N	O
fluid	NN	fluid	fluid	fluid	N	O
(	(	(	(	(	N	O
CSF	NNP	csf	csf	csf	N	O
)	)	)	)	)	N	O
testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
JC	NNP	jc	jc	jc	N	O
viral	JJ	viral	viral	viral	N	O
DNA	NNP	dna	dna	dna	N	O
by	IN	by	by	by	N	O
polymerase	NN	polymerase	polymerase	polymeras	N	O
chain	NN	chain	chain	chain	N	O
reaction	NN	reaction	reaction	reaction	N	O
(	(	(	(	(	N	O
PCR	NNP	pcr	pcr	pcr	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
brain	NN	brain	brain	brain	N	O
biopsy	NN	biopsy	biopsy	biopsi	Y	O
.	.	.	.	.	N	O

Consultation	NN	consultation	consultation	consult	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
specialist	NN	specialist	specialist	specialist	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
neurologist	JJ	neurologist	neurologist	neurologist	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
infectious	JJ	infectious	infectious	infecti	N	O
disease	NN	disease	disease	diseas	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
suspected	JJ	suspected	suspected	suspect	N	O
or	CC	or	or	or	N	O
confirmed	JJ	confirmed	confirmed	confirm	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
PML	NNP	pml	pml	pml	N	O
is	VBZ	is	is	is	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
,	,	,	,	,	N	O
consideration	NN	consideration	consideration	consider	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
to	TO	to	to	to	N	O
reduction	NN	reduction	reduction	reduct	N	O
or	CC	or	or	or	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
of	IN	of	of	of	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
taking	VBG	taking	taking	take	N	O
into	IN	into	into	into	N	O
account	NN	account	account	account	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
allograft	NN	allograft	allograft	allograft	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Other	JJ	other	other	other	N	O
Serious	JJ	serious	serious	seriou	N	O
Infections	NNS	infections	infection	infect	N	O

Patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	B-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
(	(	(	(	(	N	O
cytomegalovirus	JJ	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	B-AdverseReaction
[	NNP	[	[	[	N	O
CMV	NNP	cmv	cmv	cmv	N	B-AdverseReaction
]	NNP	]	]	]	N	O
and	CC	and	and	and	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fungal	JJ	fungal	fungal	fungal	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
protozoal	NN	protozoal	protozoal	protozo	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
may	MD	may	may	may	N	O
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
outcomes	JJ	outcomes	outcome	outcom	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
and	CC	and	and	and	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Prophylaxis	NNP	prophylaxis	prophylaxis	prophylaxi	Y	O
for	IN	for	for	for	N	O
cytomegalovirus	NN	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
.	.	.	.	.	N	O

Prophylaxis	NNP	prophylaxis	prophylaxis	prophylaxi	Y	O
for	IN	for	for	for	N	O
Pneumocystis	NNP	pneumocystis	pneumocystis	pneumocysti	N	O
jiroveci	NN	jiroveci	jiroveci	jiroveci	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
after	IN	after	after	after	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
.	.	.	.	.	N	O

Tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O

Tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
than	IN	than	than	than	N	O
cyclosporine	NN	cyclosporine	cyclosporine	cyclosporin	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
for	IN	for	for	for	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
and	CC	and	and	and	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
latent	JJ	latent	latent	latent	N	O
infection	NN	infection	infection	infect	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Polyoma	NNP	polyoma	polyoma	polyoma	N	O
Virus	NNP	virus	virus	viru	N	O
Nephropathy	NNP	nephropathy	nephropathy	nephropathi	Y	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
JC	NNP	jc	jc	jc	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
polyoma	NN	polyoma	polyoma	polyoma	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
associated	VBN	associated	associated	associ	N	I-AdverseReaction
nephropathy	JJ	nephropathy	nephropathy	nephropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PVAN	NNP	pvan	pvan	pvan	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
mostly	RB	mostly	mostly	mostli	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
BK	NNP	bk	bk	bk	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

PVAN	NNP	pvan	pvan	pvan	N	B-AdverseReaction
is	VBZ	is	is	is	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
serious	JJ	serious	serious	seriou	N	O
outcomes	NNS	outcomes	outcome	outcom	N	O
;	:	;	;	;	N	O
including	VBG	including	including	includ	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
and	CC	and	and	and	N	O
kidney	NN	kidney	kidney	kidney	N	B-AdverseReaction
graft	NN	graft	graft	graft	N	I-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Patient	JJ	patient	patient	patient	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
may	MD	may	may	may	N	O
help	VB	help	help	help	N	O
detect	VB	detect	detect	detect	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
PVAN	NNP	pvan	pvan	pvan	N	O
.	.	.	.	.	N	O

Reductions	NNS	reductions	reduction	reduct	N	O
in	IN	in	in	in	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
PVAN	NNP	pvan	pvan	pvan	N	O
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
that	IN	that	that	that	N	O
reduced	VBD	reduced	reduced	reduc	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
represents	VBZ	represents	represents	repres	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
functioning	NN	functioning	functioning	function	N	O
allograft	NN	allograft	allograft	allograft	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Liver	NNP	liver	liver	liver	N	O
Transplant	NNP	transplant	transplant	transplant	Y	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
in	IN	in	in	in	N	O
liver	NN	liver	liver	liver	N	O
transplant	NN	transplant	transplant	transplant	Y	O
patients	NNS	patients	patient	patient	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
]	NNP	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
liver	NN	liver	liver	liver	N	O
transplant	NN	transplant	transplant	transplant	Y	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
regimens	VBZ	regimens	regimen	regimen	N	O
with	IN	with	with	with	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
belatacept	NNS	belatacept	belatacept	belatacept	N	O
than	IN	than	than	than	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
those	DT	those	those	those	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
kidney	NN	kidney	kidney	kidney	N	O
transplant	NN	transplant	transplant	transplant	Y	O
,	,	,	,	,	N	O
along	IN	along	along	along	N	O
with	IN	with	with	with	N	O
mycophenolate	NN	mycophenolate	mycophenolate	mycophenol	N	O
mofetil	NN	mofetil	mofetil	mofetil	N	O
(	(	(	(	(	N	O
MMF	NNP	mmf	mmf	mmf	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
graft	NN	graft	graft	graft	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
tacrolimus	NN	tacrolimus	tacrolimus	tacrolimu	N	O
control	NN	control	control	control	N	O
arms	NNS	arms	arm	arm	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
two	CD	two	two	two	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
involving	VBG	involving	involving	involv	N	O
the	DT	the	the	the	N	O
liver	NN	liver	liver	liver	N	O
allograft	NN	allograft	allograft	allograft	N	O
(	(	(	(	(	N	O
one	CD	one	one	one	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
147	CD	147	147	147	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
two	CD	two	two	two	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
PTLD	NNP	ptld	ptld	ptld	N	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
140	CD	140	140	140	N	O
EBV	NNP	ebv	ebv	ebv	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
and	CC	and	and	and	N	O
MMF	NNP	mmf	mmf	mmf	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Acute	NNP	acute	acute	acut	N	O
Rejection	NNP	rejection	rejection	reject	N	O
and	CC	and	and	and	N	O
Graft	NNP	graft	graft	graft	N	B-AdverseReaction
Loss	NNP	loss	loss	loss	N	O
with	IN	with	with	with	N	O
Corticosteroid	NNP	corticosteroid	corticosteroid	corticosteroid	N	O
Minimization	NNP	minimization	minimization	minim	N	O

In	IN	in	in	in	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
experience	NN	experience	experience	experi	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
basiliximab	JJ	basiliximab	basiliximab	basiliximab	N	O
induction	NN	induction	induction	induct	N	O
,	,	,	,	,	N	O
MMF	NNP	mmf	mmf	mmf	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
minimization	NN	minimization	minimization	minim	N	O
to	TO	to	to	to	N	O
5	CD	5	5	5	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
between	IN	between	between	between	N	O
Day	NNP	day	day	day	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
Week	NNP	week	week	week	N	O
6	CD	6	6	6	N	O
post	NN	post	post	post	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
transplant	NN	transplant	transplant	transplant	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
rate	NN	rate	rate	rate	N	O
and	CC	and	and	and	N	O
grade	NN	grade	grade	grade	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	I-AdverseReaction
rejection	NN	rejection	rejection	reject	N	I-AdverseReaction
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
III	NNP	iii	iii	iii	N	I-Severity
rejection	NN	rejection	rejection	reject	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
III	NNP	iii	iii	iii	N	I-Severity
rejections	NNS	rejections	rejection	reject	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
4	CD	4	4	4	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
HLA	NNP	hla	hla	hla	N	O
mismatches	NNS	mismatches	mismatch	mismatch	N	O
.	.	.	.	.	N	O

Graft	NNP	graft	graft	graft	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
consequence	NN	consequence	consequence	consequ	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
III	NNP	iii	iii	iii	N	I-Severity
rejection	NN	rejection	rejection	reject	N	I-AdverseReaction
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
utilization	NN	utilization	utilization	util	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
experience	NN	experience	experience	experi	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Immunizations	NNS	immunizations	immunization	immun	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
NULOJIX	NNP	nulojix	nulojix	nulojix	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
but	CC	but	but	but	N	O
not	RB	not	not	not	N	O
limited	JJ	limited	limited	limit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O
intranasal	JJ	intranasal	intranasal	intranas	N	O
influenza	NN	influenza	influenza	influenza	Y	O
,	,	,	,	,	N	O
measles	NNS	measles	measles	measl	Y	O
,	,	,	,	,	N	O
mumps	NNS	mumps	mumps	mump	Y	O
,	,	,	,	,	N	O
rubella	NN	rubella	rubella	rubella	Y	O
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	O
polio	NN	polio	polio	polio	Y	O
,	,	,	,	,	N	O
BCG	NNP	bcg	bcg	bcg	N	O
,	,	,	,	,	N	O
yellow	JJ	yellow	yellow	yellow	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
varicella	NN	varicella	varicella	varicella	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
TY21a	NNP	ty21a	ty21a	ty21a	N	O
typhoid	JJ	typhoid	typhoid	typhoid	Y	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
.	.	.	.	.	N	O

